Mandate

Vinge advises CELLINK in connection with the acquisition of Ginolis

Vinge has advised CELLINK AB (publ) in connection with the acquisition of all shares in Ginolis Oy. Ginolis conducts operations in relation to automated diagnostics and provides advanced robotic solutions to the medical- and diagnostics industries.

The purchase price on a cash and debt free basis amount to EUR 70 million. Forty per cent of the purchase price will be paid with newly issued class B shares in CELLINK, with the remainder in cash.

Vinge’s team mainly consisted of Anders Strid, Johanna Hamrefält (project manager M&A), Anna Maria Lagerqvist Gahm and Alexander Lindeberg (IP), Aleksandar Bajic (M&A), Martin Svanberg (W&I) in addition to Edin Agic (Capital Markets). Krogerus Attorneys acted as local counsel in Finland.

Related

Vinge has advised Investor in connection with acquisition of shares in EQT

Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026